Skip to main content
. 1999 Mar;126(5):1214–1220. doi: 10.1038/sj.bjp.0702395

Figure 4.

Figure 4

Prevention by the KATP blocker gliquidone (3.0–6.0 μg per mouse, i.c.v.) of clonidine (0.125 mg kg−1, s.c.) and guanabenz (0.30 mg kg−1, s.c.) antinociception in the mouse hot-plate test. Each column shows the dose of gliquidone administered. Vertical lines represent s.e.mean; between 10 and 15 mice were tested. **P<0.01 in comparison with the corresponding analgesic-treated mice.